HR job title
- Research Associate Professor
- Contact Info
- 1 713 677 7522
- ORCiD
- 0000-0002-6221-7366
Rajendran, Praveen Associate Professor
Positions
- Associate Professor, Institute of Biosciences and Technology, School of Medicine
My research focuses on the discovery and development of novel therapies for colorectal cancer interception and investigating epigenetic pathways implicated in the early stages of the disease. As PI or co-Investigator on several NIH-funded grants, I laid the groundwork in identifying novel epigenetic mechanisms of dietary compounds that affect Wnt/?-catenin and DNA repair.
I also have extensive Pharma R&D expertise in developing novel anticancer drugs through close collaboration with R&D teams. As the Director of Antibody and Biopharmaceuticals Core (ABC), I support and advance the development of monoclonal antibodies.
I also have extensive Pharma R&D expertise in developing novel anticancer drugs through close collaboration with R&D teams. As the Director of Antibody and Biopharmaceuticals Core (ABC), I support and advance the development of monoclonal antibodies.
Research Areas
- Overview
- Publications
- Research
- Background
- Contact
- Other
- View All
Overview
Publications
selected publications
-
academic article
-
Mohan, N., Dashwood, R. H., & Rajendran, P.
(2024).
AZ of Epigenetic Readers: Targeting Alternative Splicing and Histone Modification Variants in Cancer. Cancers.
16(6), 1104-1104.
-
Neja, S., Dashwood, W. M., Dashwood, R. H., & Rajendran, P.
(2024).
Histone Acyl Code in Precision Oncology: Mechanistic Insights from Dietary and Metabolic Factors. Nutrients.
16(3), 396-396.
-
Zhang, S., Kapoor, S., Tripathi, C., Perez, J. T., Mohan, N., Dashwood, W. M., ... Dashwood, R.
(2023).
Targeting ACE2-BRD4 crosstalk in colorectal cancer and the deregulation of DNA repair and apoptosis. 7(1), 20.
-
Chen, Y., Li, J., Neja, S., Menon, R., Jayaraman, A., Lee, K., ... Dashwood, R.
(2022).
Abstract A013: Metabolomics of acute vs. chronic spinach intake in an Apc-mutant genetic background: linoleate and butanoate metabolites targeting HDAC activity and IFN- signaling. Cancer Prevention Research.
15(12_Supplement_2), a013-a013.
-
Kapoor, S., Damiani, E., Wang, S., Dharmanand, R., Tripathi, C., Tovar Perez, J. E., ... Dashwood, R. H.
(2022).
BRD9 Inhibition by Natural Polyphenols Targets DNA Damage/Repair and Apoptosis in Human Colon Cancer Cells. Nutrients.
14(20), 4317-4317.
-
Chen, Y., Li, J., Neja, S., Kapoor, S., Tovar Perez, J. E., Tripathi, C., ... Dashwood, R.
(2022).
Metabolomics of Acute vs. Chronic Spinach Intake in an Apc-Mutant Genetic Background: Linoleate and Butanoate Metabolites Targeting HDAC Activity and IFN- Signaling. Cells.
11(3), 573-573.
-
Demirhan, Y. E., Rajendran, P., Dashwood, W., Kapoor, S., Ulusan, A., Tripathi, C., ... Dashwood, R.
(2021).
S318 Optimized Lower Dose Combinations of Sulindac Plus Erlotinib Sustained Antitumor Efficacy and Reduced Toxicity in a Preclinical Model of FAP. 116(1), s138-s138.
-
Kapoor, S., Gustafson, T., Zhang, M., Chen, Y., Li, J., Nguyen, N., ... Dashwood, R.
(2021).
Abstract 2106: Combined deacetylase and bromodomain inhibition downregulates ERCC2 and suppresses growth of metastatic colon cancer cells. 81(13_Supplement), 2106-2106.
-
Kapoor, S., Gustafson, T., Zhang, M., Chen, Y., Li, J., Nguyen, N., ... Dashwood, R. H.
(2021).
Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells. Cancers.
13(6), 1438-1438.
-
Ulusan, A. M., Rajendran, P., Dashwood, W. M., Yavuz, O. F., Kapoor, S., Gustafson, T. A., ... Dashwood, R. H.
(2021).
Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP). 14(3), 325-336.
-
Damiani, E., Duran, M. N., Mohan, N., Rajendran, P., & Dashwood, R. H.
(2020).
Targeting Epigenetic 'Readers' with Natural Compounds for Cancer Interception. Journal of Cancer Prevention.
25(4), 189-203.
-
Johnson, G. S., Rajendran, P., & Dashwood, R. H.
(2020).
CCAR1 and CCAR2 as gene chameleons with antagonistic duality: Preclinical, human translational, and mechanistic basis. Cancer Science.
111(10), 3416-3425.
-
Johnson, G. S., Rajendran, P., Li, L. i., Chen, Y., Dashwood, W. M., Nhung, N., ... Dashwood, R. H.
(2019).
CCAR2 acetylation establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition. 79(13), 2614-2614.
-
Rajendran, P., Johnson, G., Li, L. i., Chen, Y., Dashwood, M., Nguyen, N., ... Dashwood, R.
(2019).
Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition. Cancer Research.
79(5), 918-927.
-
Okonkwo, A., Mitra, J., Johnson, G. S., Li, L. i., Dashwood, W. M., Hegde, M. L., ... Rajendran, P.
(2018).
Heterocyclic Analogs of Sulforaphane Trigger DNA Damage and Impede DNA Repair in Colon Cancer Cells: Interplay of HATs and HDACs. Molecular Nutrition and Food Research.
62(18), e1800228-1800228.
-
Ertem, F. U., Zhang, W., Chang, K., Dashwood, W., Rajendran, P., Sun, D., ... Dashwood, R. H.
(2017).
Prevention by tolfenamic acid and characterization of the molecular targets in Pirc and FAP colorectal adenomas. Cancer Research.
77(13_Supplement), 2229-2229.
-
Johnson, G. S., Li, J., Beaver, L. M., Dashwood, W. M., Sun, D., Rajendran, P., ... Dashwood, R. H.
(2017).
A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphane-treated colon cancer cells. Molecular Nutrition and Food Research.
61(4), 1600769-1600769.
-
Johnson, G. S., Li, J., Beaver, L. M., Dashwood, W. M., Sun, D., Rajendran, P., ... Dashwood, R. H.
(2017).
Front cover: A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphanetreated colon cancer cells. 61(4), 1770041-1770041.
-
Ertem, F. U., Zhang, W., Chang, K., Mohaiza Dashwood, W., Rajendran, P., Sun, D., ... Dashwood, R. H.
(2017).
Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. International Journal of Cancer.
140(2), 460-468.
-
Kim, E., Bisson, W. H., Lhr, C. V., Williams, D. E., Ho, E., Dashwood, R. H., & Rajendran, P.
(2016).
Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors. Current Topics in Medicinal Chemistry.
16(7), 714-731.
-
Ertem, F. U., Dashwood, W., Rajendran, P., Raju, G., Rashid, A., & Dashwood, R.
(2016).
Novel polypectomy system in a preclinical model of colon cancer. Cancer Research.
76(14_Supplement), 839-839.
-
Ertem, F., Dashwood, W., Rajendran, P., Raju, G., Rashid, A., & Dashwood, R.
(2016).
Development of a murine colonoscopic polypectomy model(withvideos). Gastrointestinal Endoscopy.
83(6), 1272-1276.
-
Kachhadia, V., Rajagopal, S., Ponpandian, T., Vignesh, R., Anandhan, K., Prabhu, D., ... Gopalan, B.
(2016).
Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts. 108, 274-286.
-
Rajendran, P., Dashwood, W., Li, L. i., Kang, Y., Kim, E., Johnson, G., ... Dashwood, R. H.
(2015).
Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon. Clinical Epigenetics.
7(1), 102.
-
Kang, Y., Nian, H., Rajendran, P., Kim, E., Dashwood, W. M., Pinto, J. T., ... Dashwood, R. H.
(2014).
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells. Cell Death and Disease.
5(10), e1476-e1476.
-
Balasubramanian, G., Kilambi, N., Rathinasamy, S., Rajendran, P., Narayanan, S., & Rajagopal, S.
(2014).
Quinolone-based HDAC inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry.
29(4), 555-562.
-
Rajendran, P., Kidane, A. I., Yu, T., Dashwood, W., Bisson, W. H., Lhr, C. V., ... Dashwood, R. H.
(2013).
HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates. Epigenetics.
8(6), 612-623.
-
Gopalan, B., Ponpandian, T., Kachhadia, V., Bharathimohan, K., Vignesh, R., Sivasudar, V., ... Rajagopal, S.
(2013).
Discovery of adamantane based highly potent HDAC inhibitors. Bioorganic and Medicinal Chemistry Letters.
23(9), 2532-2537.
-
Rajendran, P., Ho, E., Williams, D. E., & Dashwood, R. H.
(2011).
Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clinical Epigenetics.
3(1), 4.
-
Rajendran, P., Williams, D. E., Ho, E., & Dashwood, R. H.
(2011).
Metabolism as a key to histone deacetylase inhibition. Critical Reviews in Biochemistry and Molecular Biology.
46(3), 181-199.
-
Rajendran, P., Delage, B., Dashwood, W. M., Yu, T., Wuth, B., Williams, D. E., Ho, E., & Dashwood, R. H.
(2011).
Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly. Molecular Cancer.
10(1), 68.
-
Chetan, B., Bunha, M., Jagrat, M., Sinha, B. N., Saiko, P., Graser, G., ... Jayaprakash, V.
(2010).
Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity. Bioorganic and Medicinal Chemistry Letters.
20(13), 3906-3910.
-
Jaggi, M., Prasad, S., Singh, A. T., Praveen, R., Dutt, S., Mathur, A., ... Burman, A. C.
(2008).
Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors. Investigational New Drugs.
26(6), 489-504.
-
Singh, A. T., Jaggi, M., Prasad, S., Dutt, S., Singh, G., Datta, K., ... Burman, A. C.
(2008).
Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas. Investigational New Drugs.
26(6), 505-516.
-
Rajendran, P., Jaggi, M., Singh, M. K., Mukherjee, R., & Burman, A. C.
(2008).
Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Investigational New Drugs.
26(1), 25-34.
-
Gurjar, M. K., Wakharkar, R. D., Singh, A. T., Jaggi, M., Borate, H. B., Shinde, P. D., ... Burman, A. C.
(2007).
Synthesis and evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anticancer agents. Journal of Medicinal Chemistry.
50(8), 1744-1753.
-
Prasad, S., Mathur, A., Gupta, N., Jaggi, M., Singh, A. T., Rajendran, P., ... Mukherjee, R.
(2007).
Bombesin analogs containing alpha-amino-isobutyric acid with potent anticancer activity. Journal of Peptide Science.
13(1), 54-62.
-
Mukherjee, R., Jaggi, M., Siddiqui, M., Srivastava, S. K., Rajendran, P., Vardhan, A., & Burman, A. C.
(2004).
Synthesis and Cytotoxic Activity of 3OAcyl/3hydrazine/2bromo/20,29dibromo Betulinic Acid Derivatives. ChemInform.
35(49), no-no.
-
Mukherjee, R., Jaggi, M., Rajendran, P., Srivastava, S. K., Siddiqui, M., Vardhan, A., & Burman, A. C.
(2004).
Synthesis of 3OAcyl/3Benzylidene/3Hydrazone/3Hydrazine/17Carboxyacryloyl Ester Derivatives of Betulinic Acid as antiAngiogenic Agents. ChemInform.
35(41), no-no.
-
Mukherjee, R., Jaggi, M., Rajendran, P., Siddiqui, M., Srivastava, S. K., Vardhan, A., & Burman, A. C.
(2004).
Betulinic Acid and Its Derivatives as antiAngiogenic Agents. ChemInform.
35(36), no-no.
-
Mukherjee, R., Jaggi, M., Siddiqui, M., Srivastava, S. K., Rajendran, P., Vardhan, A., & Burman, A. C.
(2004).
Synthesis and cytotoxic activity of 3-O-acyl/3-hydrazine /2-bromo/20,29-dibromo betulinic acid derivatives. Bioorganic and Medicinal Chemistry Letters.
14(15), 4087-4091.
-
Mukherjee, R., Jaggi, M., Rajendran, P., Srivastava, S. K., Siddiqui, M., Vardhan, A., & Burman, A. C.
(2004).
Synthesis of 3-O-acyl/3-benzylidene/3-hydrazone/3-hydrazine/17-carboxyacryloyl ester derivatives of betulinic acid as anti-angiogenic agents. Bioorganic and Medicinal Chemistry Letters.
14(12), 3169-3172.
-
Mukherjee, R., Jaggi, M., Rajendran, P., Siddiqui, M., Srivastava, S. K., Vardhan, A., & Burman, A. C.
(2004).
Betulinic acid and its derivatives as anti-angiogenic agents. Bioorganic and Medicinal Chemistry Letters.
14(9), 2181-2184.
-
Mohan, N., Dashwood, R. H., & Rajendran, P.
(2024).
AZ of Epigenetic Readers: Targeting Alternative Splicing and Histone Modification Variants in Cancer. Cancers.
16(6), 1104-1104.
-
conference paper
-
Chen, Y., Li, J., Neja, S., Menon, R., Jayaraman, A., Lee, K., ... Dashwood, R.
(2022).
Metabolomics of acute vs. chronic spinach intake in an Apc-mutant genetic background: linoleate and butanoate metabolites targeting HDAC activity and IFN- signaling. Cancer Prevention Research.
-
Chen, Y., Li, J., Neja, S., Menon, R., Jayaraman, A., Lee, K., ... Dashwood, R.
(2022).
Metabolomics of acute vs. chronic spinach intake in an Apc-mutant genetic background: linoleate and butanoate metabolites targeting HDAC activity and IFN- signaling. Cancer Prevention Research.
-
Kapoor, S., Gustafson, T., Zhang, M., Chen, Y., Li, J., Nhung, N., ... Dashwood, R.
(2021).
Combined deacetylase and bromodomain inhibition downregulates ERCC2 and suppresses growth of metastatic colon cancer cells. Cancer Research.
-
Demirhan, Y. E., Rajendran, P., Dashwood, W., Kapoor, S., Ulusan, A., Tripathi, C., ... Dashwood, R.
(2021).
Optimized Lower Dose Combinations of Sulindac Plus Erlotinib Sustained Antitumor Efficacy and Reduced Toxicity in a Preclinical Model of FAP. AMERICAN JOURNAL OF GASTROENTEROLOGY.
S138-S138.
-
Rajendran, P., Damiani, E., Wang, S., Dashwood, W., & Dashwood, R. H.
(2020).
Dietary polyphenols as epigenetic 'reader' inhibitors. Cancer Research.
3477-3477.
-
Rajendran, P., Ulusan, A., Dashwood, W., Kapoor, S., Mohammed, A., Sei, S., ... Dashwood, R. H.
(2020).
Optimization of dosing regimens of sulindac in combination with erlotinib for small intestine and colorectal cancer prevention. Cancer Research.
21-21.
-
Johnson, G. S., Rajendran, P., Li, L. i., Chen, Y., Dashwood, W. M., Nguyen, N., ... Dashwood, R. H.
(2019).
Abstract 2614: CCAR2 acetylation establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition. 2614-2614.
-
Ulusan, A., Rajendran, P., Dashwood, W., Mohammed, A., Sei, S., Brown, P. H., Vilar-Sanchez, E., & Dashwood, R. H.
(2019).
Abstract 5074: Optimizing erlotinib plus sulindac dosing regimens in a preclinical model of FAP. 5074-5074.
-
Ulusan, A., Rajendran, P., Dashwood, W., Mohammed, A., Sei, S., Brown, P. H., Vilar-Sanchez, E., & Dashwood, R. H.
(2019).
Optimizing erlotinib plus sulindac dosing regimens in a preclinical model of FAP. Cancer Research.
5074-5074.
-
Kaiser, M. C., Rajendran, P., Dashwood, M. W., Levine, M. A., Michaels, A., Frei, B., & Dashwood, R. H.
(2013).
An epigenetic perspective on pharmacologic ascorbate in colon cancer. The FASEB Journal.
248.3-248.3.
-
Rajendran, P., Kidane, A. I., Yu, T., Dashwood, W., Ho, E., Williams, D. E., & Dashwood, R. H.
(2012).
Differential effects of sulforaphane and related isothiocyanates on HDAC turnover and the DNA damage response in colon cancer cells. Cancer Research.
lb-184-lb-184.
-
Jaggi, M., Singh, A. T., Prasad, S., Rajendran, P., Dutt, S., Burman, A. C., & Mukherjee, R.
(2005).
Anticancer activity of DRF7295: A peptide combination targeting multiple neuropeptide receptors in gastrointestinal cancers. CLINICAL CANCER RESEARCH.
9081S-9082S.
-
Singh, A. T., Jaggi, M., Prasad, S., Singh, G., Dutta, K., Rajendran, P., Burman, A. C., & Mukherjee, R.
(2005).
DRF7295: A novel peptide based signal transcluction modulator for the treatment of gastrointestinal carcinomas. CLINICAL CANCER RESEARCH.
9010S-9010S.
-
Chen, Y., Li, J., Neja, S., Menon, R., Jayaraman, A., Lee, K., ... Dashwood, R.
(2022).
Metabolomics of acute vs. chronic spinach intake in an Apc-mutant genetic background: linoleate and butanoate metabolites targeting HDAC activity and IFN- signaling. Cancer Prevention Research.
-
patent
-
RAJAGOPAL SRIRAM, .., PRAVEEN RAJENDRAN, .., RAJAGOPAL SRIDHARAN, .., KACHHADIA VIRENDRA, .., PONPANDIA THANASEKARAN, .., KEERI ABDUL RAHEEM, .., ANANDHAN KARNAMBARAM, .., & DAIVASIGAMANI PRABHU.
(2010).
HISTONE DEACETYLASE INHIBITORS
-
RAJAGOPAL SRIDHARAN, .., SELVAKUMAR THANGAPAZHAM, .., BHARATHIMOHAN KUPPUSAMY, .., KACHHADIA VIRENDRA, .., RAJAGOPAL SRIRAM, .., PRAVEEN RAJENDRAN, .., & BALAJI RAMACHANDRAN.
(2008).
STILBENE DERIVATIVES AS PSTAT3/IL-6 INHIBITORS
-
RAJAGOPAL SRIDHARAN, .., SELVAKUMAR THANGAPAZHAM, .., BHARATHIMOHAN KUPPUSAMY, .., KACHHADIA VIRENDRA, .., RAJAGOPAL SRIRAM, .., PRAVEEN RAJENDRAN, .., & BALAJI RAMACHANDRAN.
(2008).
STILBENE DERIVATIVES AS PSTAT3/IL-6 INHIBITORS
-
RAJAGOPAL SRIDHARAN, .., KACHHADIA VIRENDRA, .., PONPANDIAN THANASEKARAN, .., KEERI ABDUL RAHEEM, .., ANANDHAN KARNAMBARAM, .., RAJAGOPAL SRIRAM, .., PRAVEEN RAJENDRAN, .., & DAIVASIGAMANI PRABHU.
(2008).
HISTONE DEACETYLASE INHIBITORS
-
RAJAGOPAL SRIDHARAN, .., KACHHADIA VIRENDRA, .., PONPANDIAN THANASEKARAN, .., KEERI ABDUL RAHEEM, .., ANANDHAN KARNAMBARAM, .., RAJAGOPAL SRIRAM, .., PRAVEEN RAJENDRAN, .., & DAIVASIGAMANI PRABHU.
(2008).
HISTONE DEACETYLASE INHIBITORS
-
RAJAGOPAL SRIDHARAN, .., KACHHADIA VIRENDRA, .., PONPANDIAN THANASEKARAN, .., KEERI ABDUL RAHEEM, .., ANANDHAN KARNAMBARAM, .., RAJAGOPAL SRIRAM, .., PRAVEEN RAJENDRAN, .., & DAIVASIGAMANI PRABHU.
(2008).
HISTONE DEACETYLASE INHIBITORS
-
RAJAGOPAL SRIDHARAN, .., KACHHADIA VIRENDRA, .., PONPANDIAN THANASEKARAN, .., KEERI ABDUL RAHEEM, .., ANANDHAN KARNAMBARAM, .., RAJAGOPAL SRIRAM, .., PRAVEEN RAJENDRAN, .., & DAIVASIGAMANI PRABHU.
(2008).
HISTONE DEACETYLASE INHIBITORS
-
KACHHADIA VIRENDRA, .., PRAVEEN RAJENDRAN, .., DAIVASIGAMANI PRABHU, .., RAJAGOPAL SRIRAM, .., KEERI ABDUL RAHEEM, .., PONPANDIAN THANASEKARAN, .., RAJAGOPAL SRIDHARAN, .., & ANANDHAN KARNAMBARAM.
(2008).
Histone deacetylase inhibitors
-
RAMA MUKHERJEE, .., SIDDIQUI MOHAMMAD JAMSHED AHMED, .., SINGH ANU T, .., KUMAR SINGH MANOJ, .., KUMAR JAJOO HEMANT, .., VIVEK KUMAR, .., ... NIDHI RANI.
(2007).
Novel betullnic acid derivatives A-ring-condensed to a heterocyclic group
-
RAMA MUKHERJEE, .., SIDDIQUI MOHAMMAD JAMSHED AHMED, .., SINGH ANU T, .., KUMAR SINGH MANOJ, .., KUMAR JAJOO HEMANT, .., VIVEK KUMAR, .., ... NIDHI RANI.
(2007).
Novel betullnic acid derivatives A-ring-condensed to a heterocyclic group
-
RAJAGOPAL SRIRAM, .., PRAVEEN RAJENDRAN, .., RAJAGOPAL SRIDHARAN, .., KACHHADIA VIRENDRA, .., PONPANDIA THANASEKARAN, .., KEERI ABDUL RAHEEM, .., ANANDHAN KARNAMBARAM, .., & DAIVASIGAMANI PRABHU.
(2010).
HISTONE DEACETYLASE INHIBITORS
Research
investigator on
Background
education and training
- Ph.D. in Pharmacology, Birla Institute of Technology and Science, Pilani - Goa Campus - (Sancoale, India) 2007
Contact
first name
- Praveen
has last name
- Rajendran
mailing address
-
Texas A&M Health Science Center
Ibt - Cedp - Dashwood
1201 TAMUS
Houston, TX 77030-3303
USA
Other
- prajendran@tamu.edu